Bioidentical Hormone Replacement Therapy (BHRT): The Complete Clinical Guide

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·18 min read

Bioidentical hormone replacement therapy (BHRT) is the clinical use of hormones that are structurally identical to the ones the human body makes itself — primarily estrogen, progesterone, and testosterone — to relieve the symptoms that follow hormonal decline. For most patients that decline arrives with perimenopause and menopause in women and andropause in men, but it also accompanies surgical menopause, hypogonadism, and other endocrine conditions. The goal is not to chase a number on a lab report; it is to restore signaling the body has lost, guided by symptoms and trends over time.

This pillar guide is written for clinicians evaluating whether to add hormone therapy to their practice, and for the informed patients researching it for themselves. Because hormone therapy is a Your-Money-or-Your-Life medical topic, we are deliberate about what the evidence supports, where the data are thin, and where decades of fear trace back to a single study that used the wrong molecule. Nothing here is medical advice or a dosing protocol — specific dosing, titration, and pellet specifications stay in clinical training. This is orientation and clinical education.

What is bioidentical hormone replacement therapy?

Hormones are chemical messengers made by the endocrine glands — the pituitary, thyroid, adrenals, pancreas, ovaries, and testes — that travel through the bloodstream to target cells, bind specific receptors, and trigger a cascade of biological responses. They maintain homeostasis and regulate metabolism, growth, mood, bone density, and reproduction. Production is governed by feedback loops: the hypothalamus and pituitary monitor circulating levels and signal the glands to dial output up or down to keep hormones within a narrow range. When that range collapses with age, symptoms follow.

The word that does the heavy lifting in BHRT is bioidentical. A bioidentical hormone is one whose molecular structure is identical to the hormone your own glands produce, so it binds receptors and is metabolized the same way endogenous hormones are. That is a meaningful distinction from much of conventional hormone therapy, which often uses synthetic or animal-derived hormones — molecules tweaked just enough to be patentable. As Dr. Betsy Greenleaf, Empire's Director of Anti-Aging, frames it in the hormone pellet curriculum, non-bioidentical hormones exist largely for business reasons: a naturally occurring molecule cannot be patented, but an altered one can be. The problem is that the altered molecule does not always behave like the original in the body.

BHRT is therefore best understood not as a single drug but as a strategy: identify which hormones a patient has lost, replace them with structurally identical versions, choose a delivery method that fits the patient, and follow symptoms and trends over time rather than treating a lab value as an absolute. The rest of this guide walks through each piece of that strategy.

The hormones BHRT addresses

Sex hormones regulate far more than reproduction. They influence bone density, lipid metabolism, mood, cognition, and cardiovascular health — which is why their decline produces such a broad, often confusing symptom picture. Importantly, all individuals carry estrogen, progesterone, and testosterone; the difference between the sexes is proportion, not presence. BHRT works across that full panel.

Estrogen and estradiol

Estrogen is not one molecule but three: estradiol, the most bioactive and the one most commonly supplemented; estrone, less active and produced partly in adipose tissue; and estriol, the weakest but with some protective effect on breast tissue. In women, falling estrogen drives the hallmark menopausal symptoms — hot flashes, night sweats, sleep disruption, mood changes, vaginal and tissue dryness, and bone loss. Men carry estrogen too, and excess can present as gynecomastia or erectile changes. How a patient metabolizes estrogen matters as much as how much they have: the 4-hydroxyestrone pathway produces genotoxic metabolites associated with higher cancer risk, which is why metabolism testing and protective strategies are part of thoughtful estrogen prescribing. Our estrogen replacement therapy guide covers this in depth.

Progesterone

Progesterone prepares the uterus for implantation, stabilizes the endometrium, and supports mood and sleep — the corpus luteum produces it in the second half of the menstrual cycle. In BHRT it plays a critical protective role: in a woman with a uterus, unopposed estrogen raises endometrial cancer risk, so progesterone is used to balance it. The bioidentical-versus-synthetic distinction is sharpest here. Synthetic medroxyprogesterone is associated with weight gain, anxiety, and depression and was the agent implicated in the Women's Health Initiative; micronized bioidentical progesterone is not associated with the same effects. See the progesterone therapy guide.

Testosterone — in both sexes

Testosterone is not a male-only hormone. It declines in men with age — roughly 38% of men over 45 experience hypogonadism — producing fatigue, low libido, lost muscle mass, increased body fat, and reduced bone density. It also declines in women as the ovaries fail, where low testosterone presents as fatigue, low libido, mood changes, and loss of muscle. Dr. Greenleaf adds an important caution: testosterone is too often treated as the single answer to low sex drive, when libido is a far more complex subject, and patients may not see the improvement they expect from raising testosterone alone. Read more in the testosterone replacement therapy guide.

The rest of the picture: thyroid, DHEA, cortisol

Sex hormones do not operate in isolation. The full hormone pathway begins with cholesterol — vilified, but actually the parent molecule of every hormone downstream — flowing into pregnenolone and progesterone before converting into testosterone and estrogen. The key insight from the curriculum is that this is not a one-way street: under sympathetic (fight-or-flight) activation, the body diverts production toward cortisol, straining sex-hormone output. As Dr. Greenleaf puts it, hormone balance and chronic stress cannot coexist — one of the first things to investigate in a non-responder. Thyroid hormone governs metabolism and is screened alongside sex hormones, and DHEA, an adrenal precursor, becomes the major source of postmenopausal testosterone. A complete BHRT workup reviews this whole system, not three hormones in a vacuum.

Bioidentical vs synthetic hormones

This is the distinction patients ask about most, and it deserves an honest answer rather than marketing on either side. Bioidentical hormones are structurally identical to endogenous estradiol, progesterone, and testosterone. Synthetic hormones — including the conjugated equine ("horse") estrogens and progestins of conventional therapy — are altered molecules. Those alterations are not cosmetic: synthetic hormones often have a higher binding affinity to receptors, which can make measured hormone levels look higher than they functionally are, and several are metabolized down more toxic pathways and are believed to provoke inflammatory reactions. Many of the side effects people associate with "hormones" — clotting and cancer foremost — are thought to be substantially driven by these synthetic analogs.

The cleanest illustration is progesterone. Synthetic medroxyprogesterone was the agent in the Women's Health Initiative arm that was halted for a rise in cancers and heart disease; micronized bioidentical progesterone is not associated with those same signals. That single substitution explains a large share of the fear patients still carry into the exam room.

Honesty requires a caveat, though: "bioidentical" is not a synonym for "risk-free," and long-term head-to-head outcome trials comparing bioidentical and synthetic regimens are limited. Bioidentical hormones still carry the contraindications discussed below, and a bioidentical molecule delivered carelessly is not safe simply because of its structure. Our dedicated bioidentical vs synthetic hormones guide unpacks the chemistry, the WHI history, and the evidence in full.

Delivery methods: pellets, creams, injections, patches, and oral

The same hormone behaves very differently depending on how it is delivered, because route determines bioavailability, peaks and troughs, and the burden placed on the liver and gut. No single method is best for every patient; the choice is part of the clinical decision.

• Pellets — compounded bioidentical testosterone or estradiol mixed with a slow-release filler and inserted under the skin. They release hormone steadily for roughly three to six months, deliver high bioavailability, bypass the liver and gut, and require no daily compliance. The trade-offs are real: insertion is a minor surgical procedure, a pellet cannot be easily removed or dose-adjusted once placed, and absorption can vary patient to patient, pharmacy to pharmacy, and batch to batch, which raises the stakes on dosing.
• Creams and gels — transdermal, easy to titrate day to day, and able to avoid first-pass liver metabolism, but dependent on consistent application and absorption.
• Injections — effective and flexible, though they tend to produce peaks and troughs between doses; short-acting esters such as testosterone propionate require frequent dosing.
• Patches — transdermal and convenient, sharing the liver-sparing advantage of other transdermal routes.
• Oral — convenient but constrained: oral testosterone has an affinity for the liver and carries hepatotoxicity concerns, so it is generally not recommended, and oral routes place more strain on first-pass metabolism than transdermal or pellet delivery.

Pellets draw the most clinical interest because of one property the others struggle to match: steady-state release. As Dr. Greenleaf notes, that steadiness is both the advantage and the catch. Eliminating the daily ups and downs is convenient, but the body is designed around fluctuation — the monthly cycle in women, the morning peak in men — and receptors can begin to "tune out" a hormone held flat at steady state, raising the risk of overcorrection. Used well, pellets are powerful; used carelessly, that same steadiness is a liability. Go deeper in the hormone pellet therapy guide and the step-by-step pellet insertion procedure guide.

Hormone therapy guides

This Resource Center publishes in-depth, evidence-reviewed guides across the BHRT landscape — the major hormones, the bioidentical-versus-synthetic debate, the delivery methods, and the patient populations. Use the directory below to go deeper on any topic.

Benefits & what the evidence shows

The strongest and most consistent benefit of hormone therapy is symptom relief. Restoring estradiol reliably reduces hot flashes, night sweats, sleep disturbance, mood swings, and vaginal and tissue dryness in menopausal women; restoring testosterone improves energy, libido, muscle mass, and body composition in appropriately selected men and women. These are the outcomes patients feel, and they are the legitimate core of the therapy.

Beyond symptoms, estrogen's role in bone density is well established — hormone therapy is recognized as protective against the bone loss that accelerates after menopause, which is why patients with osteoporosis are among the better candidates. Sex hormones also influence lipid metabolism, cognition, and cardiovascular physiology, and many patients report improvements in mood and well-being that track with progesterone and balanced estrogen.

Honesty requires hedging the broader claims. Hormone therapy is not proven to be a general anti-aging or longevity intervention, and benefit beyond symptom relief and bone protection is more variable and patient-dependent. Outcome data also differ by delivery method — pellets, for example, are widely used but have a thinner long-term randomized evidence base than some transdermal regimens. The right framing for patients is that BHRT is an effective, well-targeted tool for hormone-deficiency symptoms and bone, not a guarantee of broad systemic rejuvenation.

Safety, risks, and the WHI context

No conversation about hormone therapy is honest without the Women's Health Initiative (WHI). In the early 2000s, the WHI's estrogen-plus-progestin arm was stopped early for an observed rise in breast cancer, heart disease, and clots — and the headlines that followed frightened a generation of women and clinicians away from hormones entirely. The crucial detail, emphasized throughout the curriculum, is what the study used: oral conjugated equine estrogens plus synthetic medroxyprogesterone — not bioidentical micronized progesterone, and not transdermal estradiol. The risks observed cannot be assumed to transfer cleanly to bioidentical, transdermal, or pellet regimens, and subsequent analysis has substantially nuanced the original alarm. At the same time, the WHI is not something to wave away: it is a genuine signal that hormones carry real cardiovascular and oncologic considerations that demand respect.

Each hormone carries its own risk profile. Testosterone can cause fluid retention, worsen or unmask sleep apnea, raise red blood cell count and cholesterol, and in men suppress fertility. Estrogen, unopposed in a woman with a uterus, raises endometrial cancer risk — the reason progesterone is non-negotiable for uterine protection in those patients. The relationship between testosterone and prostate cancer is widely discussed but, as Dr. Greenleaf notes, not fully understood, and prostate cancer can be hormone-stimulated — another reason for appropriate screening and caution.

Pellet delivery adds procedural risk on top of pharmacologic risk: it is a surgical procedure, pellets are difficult to reverse, and because they are not individually FDA-approved or regulated products, informed consent must be thorough. The curriculum is explicit that consent should be reviewed with the patient rather than handed across the desk — covering what a pellet is, that it is not FDA-approved, the cancer and clot questions, procedural risks ranging from common to rare (up to hospitalization, severe disability, and death), the difficulty of reversal, and the alternatives. That is the standard of care, not a formality.

Candidacy, contraindications & monitoring

The ideal BHRT candidates are menopausal women with symptoms, andropausal men with symptomatic hypogonadism, patients with osteoporosis, and those with medical conditions that cause hormonal imbalance such as premature menopause. Perimenopausal women improve too, but because pregnancy is still possible, contraception has to be addressed first — and the curriculum stresses that oral birth control hormones are not bioequivalent to bioidentical replacement and carry their own synthetic-hormone risks.

Contraindications are firm: hormone-sensitive cancers, a history of blood clots, stroke, or heart disease, liver disease, pregnancy or breastfeeding, unexplained vaginal bleeding, and allergy to pellet components. Before pellet placement specifically, patients should be current on age-appropriate screening — mammograms, Pap tests, prostate screening, colonoscopy — and any bleeding risk evaluated, with blood thinners coordinated and held in advance under the prescribing physician's guidance.

Monitoring is where good hormone medicine is won or lost. Baseline labs are drawn before therapy, and Dr. Greenleaf's practice draws both serum and dried-urine testing at baseline, using dried-urine results for clinical decisions while keeping serum on hand. The governing principle is that hormone levels are not absolutes: they should be interpreted against the patient's symptoms, with trends followed over time rather than a single value chased. Estrogen-metabolism testing can identify patients shunting down the higher-risk 4-hydroxy pathway so that protective strategies can be added. We deliberately do not publish specific dosing numbers, titration schedules, or pellet specifications here — those are taught, with the clinical reasoning behind them, in Empire's hormone training.

How much does BHRT cost?

For patients, BHRT is frequently a cash-pay service. Pellet therapy in particular is often more expensive than creams or injections and is not always covered by insurance, and ongoing hormone-metabolism testing — valuable for clinical decisions — is also commonly out of pocket. Cost varies with the hormones used, the delivery method, the compounding pharmacy, and the monitoring schedule, so an honest answer is that it is protocol-specific and best confirmed with the prescribing practice rather than reduced to a single figure.

For providers, the economics are a real part of why hormone therapy is one of the fastest-growing service lines in functional and anti-aging medicine. Pellet insertion is performed every three to six months as a recurring in-office procedure, and the service is largely cash-pay with healthy margins. There is also a startup-cost reality: reusable metal trocars run a few hundred dollars and steam sterilizers can cost several thousand, so the curriculum walks through instrumentation choices and the disposable-versus-reusable economics. As always, margin is only legitimate when the underlying care is properly trained, sourced, and consented.

How providers get trained

Licensed physicians, nurse practitioners, physician assistants, and nurses can all add BHRT to their scope with appropriate training. Hormone prescribing demands command of the physiology — the full cholesterol-to-sex-hormone pathway, estrogen metabolism, the stress-cortisol axis, and the bioidentical-versus-synthetic distinction — while pellet therapy adds a procedural skill set that has to be learned hands-on: instrumentation, sterile workflow, insertion technique, aftercare, and bruise and complication management. A strong program teaches all of it together, alongside patient selection, monitoring, and the consent standard the procedure requires.

Empire's hormone curriculum is structured exactly this way and sits within the broader Academy of Anti-Aging & Functional Medicine, alongside peptide therapy, medical weight loss, and IV nutrient therapy — areas that overlap with hormone health more than they appear to. To go deeper on any single topic, explore the guides in the directory above or return to the Resource Center as new guides publish.